PARTI OVERVIEW We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements. CORPORATE I...
Q2 FY2026 — expected 2026-09-12
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | NVCT | discussed_in_filing Cybersecurity | |
| topic_mention | NVCT | discussed_in_filing Trusted Computing | |
| topic_mention | NVCT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | NVCT | discussed_in_filing Regulation | |
| topic_mention | NVCT | discussed_in_filing Healthcare & Bio | |
| topic_mention | NVCT | discussed_in_filing Networking | |
| topic_mention | NVCT | discussed_in_filing Sovereign & Government | |
| topic_mention | NVCT | discussed_in_filing Cybersecurity | |
| topic_mention | NVCT | discussed_in_filing Trusted Computing | |
| topic_mention | NVCT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | NVCT | discussed_in_filing Regulation | |
| topic_mention | NVCT | discussed_in_filing Healthcare & Bio | |
| topic_mention | NVCT | discussed_in_filing Networking | |
| topic_mention | NVCT | discussed_in_filing Sovereign & Government | |
| topic_mention | NVCT | discussed_in_filing Cybersecurity | |
| topic_mention | NVCT | discussed_in_filing Trusted Computing | |
| topic_mention | NVCT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | NVCT | discussed_in_filing Regulation | |
| topic_mention | NVCT | discussed_in_filing Healthcare & Bio | |
| topic_mention | NVCT | discussed_in_filing Networking |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001104659-26-013044 | EDGAR | 58K words |
| 2025-02-25 | 2024-12-31 | 0001558370-25-001496 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001558370-24-002497 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001558370-23-003181 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001104659-22-037110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-105939 | EDGAR | 35K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010203 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001558370-25-006497 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001558370-24-014340 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-010971 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007072 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018124 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014266 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009133 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016755 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013018 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001410578-22-001377 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-11 | 0001104659-26-013049 | EDGAR | 2K words |
| 2025-11-04 | 0001104659-25-105953 | EDGAR | — |
| 2025-09-25 | 0001104659-25-093144 | EDGAR | — |
| 2025-08-05 | 0001104659-25-073967 | EDGAR | — |
| 2025-06-13 | 0001104659-25-059435 | EDGAR | — |
| 2025-05-09 | 0001104659-25-046845 | EDGAR | — |
| 2025-05-06 | 0001104659-25-044838 | EDGAR | — |
| 2025-02-25 | 0001104659-25-016779 | EDGAR | — |
| 2025-02-06 | 0001104659-25-009813 | EDGAR | — |
| 2024-11-05 | 0001104659-24-114097 | EDGAR | — |
64 total filings indexed. 37 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001875558 |
| Ticker | NVCT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report